

Binghe Xu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1626898/publications.pdf>

Version: 2024-02-01

179
papers

6,726
citations

172457

29
h-index

74163

75
g-index

185
all docs

185
docs citations

185
times ranked

8749
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 97-105.	2.5	6
2	Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China. <i>Breast</i> , 2022, 61, 129-135.	2.2	3
3	Retrospective literature review of primary neuroendocrine neoplasms of the breast (BNEN) in 209 Chinese patients: Treatment and prognostic factor analysis. <i>Breast</i> , 2022, 62, 93-102.	2.2	1
4	The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study. <i>International Journal of Clinical Oncology</i> , 2022, 27, 707-716.	2.2	8
5	Abstract P1-16-06: In real world, a high percentage of premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer receive chemotherapy as first-line treatment: A study of the National Cancer Center, China. <i>Cancer Research</i> , 2022, 82, P1-16-06-P1-16-06.	0.9	0
6	Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 323.	2.5	14
7	Abstract P1-08-12: The status of homologous recombination deficiency is a potential biomarker for platinum-based chemotherapy in triple-negative breast cancer. <i>Cancer Research</i> , 2022, 82, P1-08-12-P1-08-12.	0.9	0
8	Abstract P1-16-02: A randomized phase II study investigating oral metronomic vinorelbine versus conventional dosage of vinorelbine in HER2-negative metastatic breast cancer previously treated with anthracycline or taxane: clinical results and biomarker analysis. <i>Cancer Research</i> , 2022, 82, P1-16-02-P1-16-02.	0.9	0
9	Time to raise the bar: Transition rate of phase 1 programs on anticancer drugs. <i>Cancer Cell</i> , 2022, 40, 233-235.	16.8	3
10	Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 381-392.	2.5	5
11	Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients. <i>Cancer Medicine</i> , 2022, .	2.8	8
12	Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: A prospective cohort study with propensity-matched analysis. <i>International Journal of Cancer</i> , 2022, 151, 578-589.	5.1	6
13	Chemotherapy Decision-Making and Survival Outcomes in Older Women With Early Triple-Negative Breast Cancer: Evidence From Real-World Practice. <i>Frontiers in Oncology</i> , 2022, 12, 867583.	2.8	0
14	Analysis of non-sentinel lymph node status on 10-year overall survival among patients with breast cancer and sentinel lymph node metastasis. <i>Journal of Clinical Oncology</i> , 2022, 40, e12584-e12584.	1.6	0
15	Genomic landscape and peripheral blood biomarkers of advanced triple-negative breast cancer treated with immune checkpoint blockade: An exploratory analysis of the TQB2450-1b-07 trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1080-1080.	1.6	0
16	Abstract 5689: Effects of homologous recombination-related gene mutation subtypes on gene instability and the efficacy of platinum-containing regimens in triple-negative breast cancer. <i>Cancer Research</i> , 2022, 82, 5689-5689.	0.9	0
17	Abstract 5084: KMT2D and PIK3CA mutation as potential factors to predict adjuvant chemotherapy efficacy in surgical triple negative breast cancer. <i>Cancer Research</i> , 2022, 82, 5084-5084.	0.9	0
18	Pyrotinib monotherapy or pyrotinib in combination with capecitabine could significantly prolong progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1034-1034.	1.6	1

#	ARTICLE	IF	CITATIONS
19	The efficacy and safety of apatinib combined with paclitaxel and carboplatin dose-dense regimen in neoadjuvant therapy for locally advanced triple-negative breast cancer.. Journal of Clinical Oncology, 2022, 40, e12602-e12602.	1.6	0
20	Analysis of prognostic factors and survival outcomes for patients with T1N0 HER2-positive infiltrating ductal carcinoma of the breast: A real-world study with long-term follow-up.. Journal of Clinical Oncology, 2022, 40, e12530-e12530.	1.6	0
21	A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.. Journal of Clinical Oncology, 2022, 40, TPS611-TPS611.	1.6	1
22	Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR+/HER2- advanced breast cancer: A phase Ib study.. Journal of Clinical Oncology, 2022, 40, 1066-1066.	1.6	0
23	28-gene classifier model for prediction of local recurrence and distant metastasis risk in HER-2 positive operable breast cancer.. Journal of Clinical Oncology, 2022, 40, e13018-e13018.	1.6	0
24	First-in-human, phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, 3013-3013.	1.6	1
25	Prognostic Model and Nomogram for Estimating Survival of Small Breast Cancer: A SEER-based Analysis. Clinical Breast Cancer, 2021, 21, e497-e505.	2.4	10
26	Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer. Cancer Medicine, 2021, 10, 109-118.	2.8	12
27	Progress in systemic therapy for triple-negative breast cancer. Frontiers of Medicine, 2021, 15, 1-10.	3.4	16
28	Primary Trastuzumab Resistance After (Neo)adjuvant Trastuzumab-containing Treatment for Patients With HER2-positive Breast Cancer in Real-world Practice. Clinical Breast Cancer, 2021, 21, 191-198.	2.4	2
29	Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer. Cancer Biology and Medicine, 2021, 18, 849-859.	3.0	17
30	Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer. Journal of Cancer, 2021, 12, 936-945.	2.5	6
31	Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA. Cancer Biology and Medicine, 2021, 18, 875-887.	3.0	7
32	Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis. Annals of Translational Medicine, 2021, 9, 109-109.	1.7	1
33	Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective. Breast Cancer: Targets and Therapy, 2021, Volume 13, 135-150.	1.8	3
34	DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis. Annals of Translational Medicine, 2021, 9, 220-220.	1.7	11
35	Sex-Based Heterogeneity in the Clinicopathological Characteristics and Prognosis of Breast Cancer: A Population-Based Analysis. Frontiers in Oncology, 2021, 11, 642450.	2.8	1
36	Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy. BMC Cancer, 2021, 21, 341.	2.6	3

#	ARTICLE	IF	CITATIONS
37	Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 351-360.	10.7	188
38	Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 131-141.	2.3	8
39	Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial. <i>BioDrugs</i> , 2021, 35, 337-350.	4.6	21
40	A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer. <i>Biomarker Research</i> , 2021, 9, 24.	6.8	14
41	Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer. <i>Biomarker Research</i> , 2021, 9, 28.	6.8	13
42	RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1022-1022.	1.6	48
43	The emerging role of RNA N6-methyladenosine methylation in breast cancer. <i>Biomarker Research</i> , 2021, 9, 39.	6.8	22
44	Assessment of ethnic difference in the incidence of thrombocytopenia induced by trastuzumab emtansine (T-DM1): A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15096-e15096.	1.6	1
45	Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e12586-e12586.	1.6	0
46	The intra-tumor heterogeneity of ER and HER2 expression in patients with ER-positive and HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e12550-e12550.	1.6	1
47	Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1002-1002.	1.6	7
48	Endocrine therapy-based strategies with different endocrine sensitivity statuses for hormone receptor positive/HER2 negative metastatic breast cancer: A network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1062-1062.	1.6	0
49	Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 602222.	2.8	9
50	Tumor Microenvironment Subtypes and Immune-Related Signatures for the Prognosis of Breast Cancer. <i>BioMed Research International</i> , 2021, 2021, 1-12.	1.9	2
51	The molecular tumor burden index as a response evaluation criterion in breast cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 251.	17.1	19
52	Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103376.	4.4	9
53	Assessment of racial differences in the incidence of thrombocytopenia induced by trastuzumab emtansine: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 1139-1139.	1.7	4
54	Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Targeted Oncology</i> , 2021, 16, 591-599.	3.6	6

#	ARTICLE	IF	CITATIONS
55	Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nationwide multicenter study. <i>Cancer Medicine</i> , 2021, 10, 6744-6761.	2.8	5
56	Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression. <i>Cancer Letters</i> , 2021, 523, 43-56.	7.2	23
57	The Landscape of Cell and Gene Therapies for Solid Tumors. <i>Cancer Cell</i> , 2021, 39, 7-8.	16.8	18
58	Clinicopathological Characteristics and Prognosis of Squamous Cell Carcinoma of the Breast: A Population-Based Analysis. <i>Cancer Control</i> , 2021, 28, 107327482110443.	1.8	3
59	Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. <i>Cancer Cell</i> , 2021, 39, 1578-1593.e8.	16.8	275
60	Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1904-1909.	30.7	65
61	In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China. <i>Frontiers in Oncology</i> , 2021, 11, 774577.	2.8	46
62	Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. <i>International Journal of Cancer</i> , 2020, 146, 1359-1368.	5.1	55
63	ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 571517.	2.8	7
64	Discrepancies in Genetic Testing Procedures of BRCA1/2 Mutations: A National Survey Across China. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 715-721.	3.8	0
65	Ganglioside Monosialic Acid Alleviates Peripheral Neuropathy Induced by Utidelone Plus Capecitabine in Metastatic Breast Cancer From a Phase III Clinical Trial. <i>Frontiers in Oncology</i> , 2020, 10, 524223.	2.8	3
66	Mutational characteristics determined using circulating tumor DNA analysis in triple-negative breast cancer patients with distant metastasis. <i>Cancer Communications</i> , 2020, 40, 738-742.	9.2	3
67	Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage. <i>Frontiers in Oncology</i> , 2020, 10, 902.	2.8	28
68	Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer. <i>Breast</i> , 2020, 53, 111-118.	2.2	8
69	Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). <i>Cancer</i> , 2020, 126, 3867-3882.	4.1	15
70	Current clinical trials on breast cancer in China: A systematic literature review. <i>Cancer</i> , 2020, 126, 3811-3818.	4.1	4
71	Clinicopathological characteristics and prognosis of breast cancer with special histological types: A surveillance, epidemiology, and end results database analysis. <i>Breast</i> , 2020, 54, 114-120.	2.2	26
72	Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	1.3	1

#	ARTICLE	IF	CITATIONS
73	Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 59.	5.2	32
74	Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China. <i>Cancer Communications</i> , 2020, 40, 260-269.	9.2	18
75	Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 67-77.	2.5	24
76	Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. <i>Scientific Reports</i> , 2020, 10, 8753.	3.3	20
77	Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China. <i>International Journal of Cancer</i> , 2020, 147, 3199-3205.	5.1	8
78	Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 689-697.	2.5	25
79	Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092599.	3.2	11
80	Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China. <i>International Journal of Cancer</i> , 2020, 147, 3490-3499.	5.1	11
81	Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers. <i>Breast</i> , 2020, 52, 17-22.	2.2	12
82	Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China. <i>Frontiers in Oncology</i> , 2020, 10, 599604.	2.8	2
83	A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 565384.	2.8	11
84	Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis. <i>Current Problems in Cancer</i> , 2020, 44, 100606.	2.0	11
85	Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1003-1003.	1.6	20
86	A phase I study of SHR6390, a cyclin-dependent kinase 4/6 inhibitor in patients with advanced breast cancer (ABC). <i>Journal of Clinical Oncology</i> , 2020, 38, 1095-1095.	1.6	1
87	Primary Tumor Surgery for Patients with De Novo Stage IV Breast Cancer can Decrease Local Symptoms and Improve Quality of Life. <i>Annals of Surgical Oncology</i> , 2020, 27, 1025-1033.	1.5	15
88	Current management of chemotherapy-induced neutropenia in adults: key points and new challenges. <i>Cancer Biology and Medicine</i> , 2020, 17, 896-909.	3.0	35
89	Validity of distress thermometer for screening of anxiety and depression in family caregivers of Chinese breast cancer patients receiving postoperative chemotherapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 476-484.	2.2	6
90	Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 485-496.	2.2	8

#	ARTICLE	IF	CITATIONS
91	HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials. <i>Annals of Translational Medicine</i> , 2020, 8, 1634-1634.	1.7	3
92	Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2610-2619.	1.6	226
93	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. <i>European Journal of Cancer</i> , 2019, 120, 20-30.	2.8	75
94	Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia. <i>Future Oncology</i> , 2019, 15, 3243-3253.	2.4	2
95	Targeted therapeutic options and future perspectives for HER2-positive breast cancer. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 34.	17.1	242
96	Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis. <i>Cancer Management and Research</i> , 2019, Volume 11, 4699-4706.	1.9	14
97	Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 5212-5220.	7.0	60
98	Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study. <i>Oncology Letters</i> , 2019, 17, 4768-4778.	1.8	16
99	Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. <i>BMC Cancer</i> , 2019, 19, 442.	2.6	26
100	Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody. <i>Thoracic Cancer</i> , 2019, 10, 1395-1401.	1.9	33
101	Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. <i>Cancer Biology and Medicine</i> , 2019, 16, 189.	3.0	16
102	Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. <i>European Journal of Cancer</i> , 2019, 112, 57-65.	2.8	56
103	Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes. <i>Cancer Medicine</i> , 2019, 8, 2074-2084.	2.8	21
104	Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-label phase 3 trial. <i>Cancer Communications</i> , 2019, 39, 1-10.	9.2	17
105	The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. <i>Cancer Communications</i> , 2019, 39, 1-10.	9.2	86
106	The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China. <i>Clinical Breast Cancer</i> , 2019, 19, e370-e375.	2.4	3
107	Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China. <i>Cancer</i> , 2019, 125, 742-749.	4.1	55
108	A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple-negative breast cancer patients with high-recurrence risk. <i>Journal of Clinical Oncology</i> , 2019, 37, 528-528.	1.6	6

#	ARTICLE	IF	CITATIONS
109	Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 759-770.	2.2	9
110	Progression-free survival as a predictor of overall survival in patients with advanced breast cancer: A real-world study from the China National Cancer Center.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12590-e12590.	1.6	0
111	Progression-free survival as a predictor of overall survival in patients with advanced breast cancer: A real-world study from the China National Cancer Center and validation in the Memorial Sloan Kettering Cancer Center Cohort.. <i>Journal of Global Oncology</i> , 2019, 5, 88-88.	0.5	0
112	The landscape of treatment and overall survival analysis of elderly patients with advanced breast cancer in China National Cancer Center.. <i>Journal of Global Oncology</i> , 2019, 5, 137-137.	0.5	0
113	Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer. <i>Thoracic Cancer</i> , 2018, 9, 613-620.	1.9	0
114	The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. <i>International Journal of Cancer</i> , 2018, 143, 184-189.	5.1	25
115	Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 1296-1304.	7.0	146
116	Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy. <i>Chinese Journal of Cancer</i> , 2018, 37, 4.	4.9	13
117	The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study. <i>Cancer Communications</i> , 2018, 38, 1-11.	9.2	16
118	Polymorphisms in <i>AURKA</i> and <i>AURKB</i> are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy. <i>Cancer Management and Research</i> , 2018, Volume 10, 3801-3808.	1.9	19
119	Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 535-544.	2.5	12
120	Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years. <i>Clinical Breast Cancer</i> , 2018, 18, e1353-e1360.	2.4	7
121	Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China. <i>International Journal of Cancer</i> , 2018, 143, 2499-2504.	5.1	12
122	Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. <i>British Journal of Cancer</i> , 2018, 119, 538-545.	6.4	111
123	Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer. <i>Cancer Medicine</i> , 2018, 7, 4420-4433.	2.8	46
124	Phase I safety and pharmacokinetic study of ciptatinib, an original dual tyrosine kinase inhibitor. <i>Thoracic Cancer</i> , 2018, 9, 1041-1047.	1.9	1
125	An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1028-1028.	1.6	19
126	An open-label, dose-escalation phase I study to evaluate RC48-ADC, a novel antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1030-1030.	1.6	10

#	ARTICLE	IF	CITATIONS
127	Impact of HER2 mutation status on personalized molecular targeted therapy in advanced breast cancers.. Journal of Clinical Oncology, 2018, 36, 1039-1039.	1.6	4
128	EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician's choice (TPC) in OlympiAD.. Journal of Clinical Oncology, 2018, 36, 1045-1045.	1.6	3
129	Integrative clinical genomics of early-onset breast cancer.. Journal of Clinical Oncology, 2018, 36, 1541-1541.	1.6	2
130	Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 327-339.	2.2	3
131	Phase III multicenter, randomized study of utidelone plus capecitabine versus capecitabine alone for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, 1003-1003.	1.6	0
132	Apatinib plus vinorelbine: A novel combination of all-oral regimen in heavily pretreated patients with metastatic HER2-negative breast cancer.. Journal of Clinical Oncology, 2018, 36, e13096-e13096.	1.6	0
133	The Demographic Features, Clinicopathological Characteristics and Cancer-specific Outcomes for Patients with Microinvasive Breast Cancer: A SEER Database Analysis. Scientific Reports, 2017, 7, 42045.	3.3	41
134	Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet Oncology, The, 2017, 18, 371-383.	10.7	43
135	Timing of paclitaxel treatment in pre-operative or post-operative does not affect survival in breast cancer patients. Thoracic Cancer, 2017, 8, 246-250.	1.9	0
136	Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New England Journal of Medicine, 2017, 377, 523-533.	27.0	2,256
137	Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis. Scientific Reports, 2017, 7, 5995.	3.3	25
138	Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. Breast Cancer Research, 2017, 19, 47.	5.0	19
139	Neuroendocrine carcinoma of the breast: a review of 126 cases in China. Chinese Journal of Cancer, 2017, 36, 45.	4.9	14
140	Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer. Oncotarget, 2017, 8, 36750-36760.	1.8	3
141	Efficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathy. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 411-418.	2.2	9
142	Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2017, 35, 3105-3112.	1.6	168
143	Young breast cancer patients who develop distant metastasis after surgery have better survival outcomes compared with elderly counterparts. Oncotarget, 2017, 8, 44851-44859.	1.8	15
144	A real-world retrospective study of apatinib plus chemotherapy in metastatic breast cancer.. Journal of Clinical Oncology, 2017, 35, e12507-e12507.	1.6	1

#	ARTICLE	IF	CITATIONS
145	Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, e15572-e15572.	1.6	8
146	Impact of High Altitude on Clinicopathological Features and Prognosis after R0 Resection for Gastric Cancer: A Population-Based Multicenter Study. Journal of Environmental Pathology, Toxicology and Oncology, 2017, 36, 1-14.	1.2	1
147	Phase II study of apatinib plus vinorelbine, a novel combination of all-oral regimen in heavily pretreated patients with metastatic HER2-negative breast cancer.. Journal of Clinical Oncology, 2017, 35, TPS1123-TPS1123.	1.6	0
148	Landscape of somatic mutations in different subtypes: Advanced breast cancer with circulating tumour DNA analysis.. Journal of Clinical Oncology, 2017, 35, e23039-e23039.	1.6	0
149	Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China. Oncotarget, 2016, 7, 57301-57309.	1.8	15
150	ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. Oncotarget, 2016, 7, 66020-66031.	1.8	75
151	Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients. Journal of Hematology and Oncology, 2016, 9, 68.	17.0	19
152	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2016, 17, 357-366.	10.7	125
153	Cardia and Non-Cardia Gastric Cancer Have Similar Stage-for-Stage Prognoses After R0 Resection: a Large-Scale, Multicenter Study in China. Journal of Gastrointestinal Surgery, 2016, 20, 700-707.	1.7	19
154	Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial. Oncotarget, 2016, 7, 60647-60656.	1.8	63
155	Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells. Oncotarget, 2016, 7, 65993-66002.	1.8	19
156	A single-nucleotide polymorphism in the 3'UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer. Oncotarget, 2016, 7, 18984-18998.	1.8	13
157	Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. Oncotarget, 2016, 7, 33391-33407.	1.8	17
158	Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study. Oncotarget, 2016, 7, 50643-50655.	1.8	10
159	Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors. Anticancer Research, 2016, 36, 6185-6194.	1.1	17
160	The Significance and Therapeutic Potential of GATA3 Expression and Mutation in Breast Cancer: A Systematic Review. Medicinal Research Reviews, 2015, 35, 1300-1315.	10.5	16
161	Association between Lymph Node Ratio and Disease Specific Survival in Breast Cancer Patients with One or Two Positive Lymph Nodes Stratified by Different Local Treatment Modalities. PLoS ONE, 2015, 10, e0138908.	2.5	7
162	Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study. PLoS ONE, 2015, 10, e0136268.	2.5	15

#	ARTICLE	IF	CITATIONS
163	In Reply. <i>Oncologist</i> , 2015, 20, 88-88.	3.7	3
164	The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors. <i>Cancer Treatment Reviews</i> , 2015, 41, 623-633.	7.7	44
165	Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial. <i>Cancer</i> , 2015, 121, 3412-3421.	4.1	15
166	Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries. <i>PLoS ONE</i> , 2015, 10, e0128345.	2.5	27
167	Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial. <i>Oncotarget</i> , 2015, 6, 18683-18692.	1.8	20
168	National consensus in China on diagnosis and treatment of patients with advanced breast cancer. <i>Annals of Translational Medicine</i> , 2015, 3, 242.	1.7	14
169	Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel. <i>PLoS ONE</i> , 2014, 9, e104870.	2.5	66
170	MicroRNA-21 Identified as Predictor of Cancer Outcome: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e103373.	2.5	55
171	A CLDN1-Negative Phenotype Predicts Poor Prognosis in Triple-Negative Breast Cancer. <i>PLoS ONE</i> , 2014, 9, e112765.	2.5	33
172	Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 580-591.	10.7	434
173	Consistent efficacy and safety of gemcitabine-paclitaxel in patients with metastatic breast cancer: A retrospective comparison of East Asian and global studies. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 330-339.	1.1	5
174	Enriched CD44+/CD24 ^{low} population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). <i>Cancer Letters</i> , 2014, 353, 153-159.	7.2	113
175	Management of Contralateral Axillary Lymph Node Metastasis from Breast Cancer: A Clinical Dilemma. <i>Tumori</i> , 2014, 100, 600-604.	1.1	23
176	Fulvestrant 250Âmg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 223-230.	2.3	24
177	Biweekly gemcitabine+paclitaxel, gemcitabine+carboplatin, or gemcitabine+cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. <i>Breast Cancer</i> , 2011, 18, 203-212.	2.9	19
178	The clinical course and treatment results of lung metastases from breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 1998, 10, 297-300.	2.2	0
179	Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysis. <i>Cancer Medicine</i> , 0, , .	2.8	3